company background image
NEU logo

Neuren Pharmaceuticals CHIA:NEU Stock Report

Last Price

AU$14.45

Market Cap

AU$1.8b

7D

-1.6%

1Y

-36.8%

Updated

31 Jan, 2025

Data

Company Financials +

Neuren Pharmaceuticals Limited

CHIA:NEU Stock Report

Market Cap: AU$1.8b

NEU Stock Overview

A biopharmaceutical company, develops drugs for the treatment of neurological disorders. More details

NEU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Neuren Pharmaceuticals Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Neuren Pharmaceuticals
Historical stock prices
Current Share PriceAU$14.45
52 Week HighAU$24.00
52 Week LowAU$10.90
Beta2.19
1 Month Change15.60%
3 Month Change18.15%
1 Year Change-36.76%
3 Year Change279.27%
5 Year Change391.50%
Change since IPO489.80%

Recent News & Updates

Recent updates

Shareholder Returns

NEUAU PharmaceuticalsAU Market
7D-1.6%-2.8%1.3%
1Y-36.8%-5.5%10.3%

Return vs Industry: NEU underperformed the Australian Pharmaceuticals industry which returned -5.5% over the past year.

Return vs Market: NEU underperformed the Australian Market which returned 10.3% over the past year.

Price Volatility

Is NEU's price volatile compared to industry and market?
NEU volatility
NEU Average Weekly Movement9.4%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement7.9%
10% most volatile stocks in AU Market16.4%
10% least volatile stocks in AU Market2.9%

Stable Share Price: NEU has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: NEU's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aJon Pilcherwww.neurenpharma.com

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.

Neuren Pharmaceuticals Limited Fundamentals Summary

How do Neuren Pharmaceuticals's earnings and revenue compare to its market cap?
NEU fundamental statistics
Market capAU$1.84b
Earnings (TTM)AU$117.29m
Revenue (TTM)AU$193.34m

15.7x

P/E Ratio

9.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NEU income statement (TTM)
RevenueAU$193.34m
Cost of RevenueAU$32.90m
Gross ProfitAU$160.44m
Other ExpensesAU$43.15m
EarningsAU$117.29m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.92
Gross Margin82.98%
Net Profit Margin60.67%
Debt/Equity Ratio0%

How did NEU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 18:27
End of Day Share Price 2025/01/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neuren Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
Melissa BensonBarrenjoey Markets Pty Limited
Tara SperanzaBell Potter